A randomized double-blind comparison of @entity3988 and @entity594 in XXXX .

@entity1 @entity308 @entity4 @entity5749 @entity3988 @entity951 @entity594 @entity453 @entity10 @entity551
A double-blind crossover trial comparing @entity3988 (360 mg/day) and @entity594 (120 mg/day) for treatment of @entity5749 was conducted in 21 of 27 @entity1 with proven @entity453 who completed the trial. All @entity1 started with a 2 week placebo period followed by a random assignment to either drug treatment for 3 weeks and subsequent crossover to the other treatment. The two drug treatment periods were separated by a 1 week placebo washout phase and the study was completed with a 1 week placebo phase. There were no significant differences between @entity1 ' responses to @entity3988 and @entity594 in relation to time to onset of @entity951 , ST @entity308 responses to exercise, @entity551 . A total of 37 adverse effects were reported with @entity594 compared with 9 with @entity3988 in the 22 @entity1 in whom drug safety was analyzed. Additionally, two @entity1 treated with @entity594 were withdrawn from study participation before crossover. There was a significant (p less than 0.05) difference with respect to incidence of @entity4 (7 of 22 @entity1 taking @entity594 , 1 of 22 taking @entity3988 ) and dizziness (7 of 22 @entity1 taking @entity594 , 0 of 22 taking @entity3988 ). The most frequent adverse effect reported with @entity3988 was rash (3 of 22 @entity1 ). Severe adverse effects were reported in four @entity1 : in one with @entity3988 (rash) and in three with @entity594 (palpitation in two and @entity10 in one). A reduction in prescribed dosage was required in 37% of @entity594 -treated compared with 6% of @entity3988 -treated @entity1 . Efficacy measures were significantly improved above placebo levels by both @entity3988 and @entity594 .(ABSTRACT TRUNCATED AT 250 WORDS)
